# OnCo record enlaza-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/enlaza-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "enlaza-therapeutics" ;
  schema:name "Enlaza Therapeutics"@en ;
  schema:description "Enlaza Therapeutics engineers protein drugs that lock permanently onto their target once they find it, which could let antibody-based cancer medicines work at lower doses with fewer side effects. Its programmes are still in laboratory development."@en ;
  schema:url <https://onco.cc/companies/enlaza-therapeutics/>, <https://enlazatx.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://enlazatx.com/>, <https://enlazatx.com/press_release/enlaza-therapeutics-launches-with-61-million-financing-to-advance-the-first-covalent-biologic-therapeutic-platform/>, <https://enlazatx.com/press_release/enlaza-therapeutics-raises-100-million-through-its-series-a-financing-led-by-the-life-sciences-group-of-j-p-morgan-private-capital/> ;
  schema:addressCountry "US" ;
  onco:sections <https://onco.cc/fronts/adcs/>, <https://onco.cc/fronts/drug-discovery/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/site-specific-conjugation/> .